

Organized by



Grupo Español de Cáncer de Pulmón

Spanish Lung Cancer Group

Plenary Session
&
VIII Educational Symposium
of the Spanish Lung Cancer Group



MADRID, 17th & 18th NOVEMBER 2016

Chair:

Dr. Mariano Provencio

Hospital Univ. Puerta de Hierro, Majadahonda (Madrid)



THURSDAY November 17th, 2016

**09.30 - 10.00 The changing field of lung cancer:
A 25 year perspective from the Spanish Lung Cancer Group**

Mariano Provencio
Hospital Univ. Puerta de Hierro, Majadahonda (Madrid)

10.00-11.35 SESSION I: NSCLC: EARLY STAGES

Chairpersons:

Florentino Hernando-Trancho
Hospital Clínico San Carlos, Madrid

Óscar Juan
Hospital Politécnic i Universitari La Fe, Valencia

**10.00-10.15 Moving forward in TNM staging for lung cancer:
effects on clinical practice and outcomes analysis.**

Ramón Ramí
Hospital Univ. Mutua de Terrassa, Terrassa (Barcelona)

**10.15-10.45 Treating Stage I:
Potential role of sublobar resections in NSCLC**

Laureano Molins
Hospital Clínic Universitari, Barcelona

Radiotherapy treatment in surgically compromised patients

Arturo Navarro
ICO, Hospital Duran i Reynals, L'Hospitalet de Llobregat (Barcelona)

10.45-11.00 Postoperative chemotherapy: what have we achieved?

Bartomeu Massutí
Hospital General Universitario, Alicante

**11.00-11.20 Prognostic and predictive factors in early disease:
could molecular biology help in the selection of patients?**

Martin Filipits
Medical University of Vienna, Vienna (Austria)

11.20-11.35 Discussion

11.35-11.45 Break

**11.45-13.40 SESSION II: MOLECULAR BIOLOGY
OF LUNG CANCER**

Chairpersons:

Eloísa Jantus
Hospital General Universitario, Valencia

José L. Ramírez
ICO, Hospital Univ. Germans Trias i Pujol, Badalona (Barcelona)

**11.45-12.05 Key Lecture: Liquid biopsy in lung cancer:
could it replace tissue rebiopsy?**

Rafael Rosell
ICO, Hospital Univ. Germans Trias i Pujol, Badalona (Barcelona)

**12.05-12.20 Next generation sequencing: how and when
in lung cancer care?**

Atocha Romero
Hospital Univ. Puerta de Hierro, Majadahonda (Madrid)

**12.20-12.40 Management approach to biological samples
in lung cancer patients**

Keith M. Kerr
Aberdeen University Medical School, Aberdeen (United Kingdom)

12.40-12.55 Different approaches for genomic analysis in lung cancer

Miguel A. Molina
Hospital Univ. Quirón Dexeus, Barcelona

**12.55- 13.05 Signalling pathways in NSCLC:
opening new therapeutic opportunities**

Enriqueta Felip
Hospital General Vall d'Hebron, Barcelona

**13.05-13.20 Metabolomics: widening the landscape
of lung cancer biology**

Antonio Pineda-Lucena
Instituto de Investigación Sanitaria La Fe, Valencia

13.20-13.40 Discussion

13.40-14.45 Lunch

**14.45-15.45 SESSION III: CURRENT SPANISH LUNG
CANCER GROUP TRIALS**

Chairpersons:

Rosario García Campelo

Complejo Hospitalario Universitario, A Coruña

Santiago Viteri

Hospital Univ. Quirón Dexeus, Barcelona

14.45-14.50 BR.31 LINC

Natividad Martínez-Banaclocha

Hospital General Universitario, Alicante

14.50-14.55 NORA

Dolores Isla

Hospital Clínico Univ. Lozano Blesa, Zaragoza

14.55-15.00 GOAL

Ana Laura Ortega

Complejo Hospitalario de Jaén

15.00-15.05 PIPSEN

Santiago Viteri

Hospital Univ. Quirón Dexeus, Barcelona

15.05-15.10 Neoadjuvant Nivolumab in IIIA Stage

Virginia Calvo

Hospital Univ. Puerta de Hierro, Majadahonda (Madrid)

15.10-15.15 C-MET

José Luis Mate

ICO, Hospital Univ. Germans Trias i Pujol, Badalona (Barcelona)

15.15-15.20 Durvalumab HIV

María González-Cao

Instituto Univ. Quirón Dexeus, Barcelona

15.20-15.25 STIMULI

Manuel Dómine

Fundación Jiménez Díaz, Madrid

15.25-15.30 SPLENDOUR

Manuel Cobo

Hospital Univ. Carlos Haya, Málaga

15.30-15.35 EAP Nivolumab

Margarita Majem

Hospital de la Santa Creu i Sant Pau, Barcelona

15.35-15.40 SELINA

Ana Blasco

Hospital General Universitario, Valencia

**15.45-17.30 SESSION IV: SMALL CELL LUNG CANCER
AND OTHER THORACIC TUMORS**

Chairpersons:

Isidoro Barneto

Hospital Univ. Reina Sofía, Córdoba

José Luis González-Larriba

Hospital Clínico San Carlos, Madrid

15.45-16.00 Update in SCLC management: any advances?

Javier De Castro

Hospital Univ. La Paz, Madrid

**16.00-16.20 Molecular biology in SCLC:
promising or unproductive field?**

Marina Garassino

Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan (Italy)

16.20-16.40 Thymic tumors: no longer neglected

Nicolas Girard

Claude Bernard University, Lyon (France)

16.40-16.55 Neuroendocrine tumors: specific approach?

José M. Sánchez

Hospital Univ. de la Princesa, Madrid

16.55-17.10 The promise of new therapies for Malignant Mesothelioma

Jordi Remon

Institut Gustave Roussy, Paris (France)

17.10-17.30 Discussion

17.30-17.50 Coffee Break

17.50-19.40 SESSION V: IMMUNOTHERAPY

Chairpersons:

Manuel Cobo

Hospital Univ. Carlos Haya, Málaga

Delvys Rodríguez

Hospital Univ. Insular de Gran Canaria, Las Palmas de Gran Canaria

17.50-18.10 Could immunotherapy improve advanced lung cancer outcomes as to catch up with other common advanced carcinomas?

Pilar Garrido

Hospital Univ. Ramón y Cajal, Madrid

18.10-18.30 Placing immunotherapy in the therapeutic strategy

Filippo De Marinis

Istituto Europeo di Oncologia, Milan (Italy)

18.30-18.45 Role of biomarkers in the treatment decision-making process

Luis Paz-Ares

Hospital Univ. 12 de Octubre, Madrid

18.45-19.05 Combining immunotherapies and other treatment approaches

Christian Rolfo

University Hospital Antwerp, Edegem (Belgium)

19.05-19.20 Immunotherapy pharmacoeconomics: a burning issue

Juan del Llano

Fundación Gaspar Casal, Madrid

19.20-19.40 Discussion

Dinner

FRIDAY November 18th, 2016

08.00-09.30 PARALLEL WORKSHOPS

08.30-09.30 SLCG Plenary Session

09.30-10.00 25 years later: Crossing new borders in lung cancer: overcoming new challenges

Rafael Rosell

ICO, Hospital Univ. Germans Trias i Pujol, Badalona (Barcelona)

10.00-11.00 SESSION VI: LOCALLY ADVANCED DISEASE

Chairpersons:

Noemí Reguart

Hospital Clínic Universitari, Barcelona

Pilar Lianes

Hospital de Mataró, Mataró (Barcelona)

**10.00-10.30 Controversy on the treatment of resectable stage III disease
*In favor of bi-modal therapy***

Ernest Nadal

ICO, Hospital Duran i Reynals, L'Hospitalet de Llobregat (Barcelona)

In favor of tri-modal therapy

Juan Coves

Hospital Son Llàtzer, Palma de Mallorca (Balears)

10.30-10.45 Potential role of new agents in locally advanced disease management

Enric Carcereny

ICO, Hospital Univ. Germans Trias i Pujol, Badalona (Barcelona)

10.45-11.00 Discussion

11.00-11.30 Coffee Break

11.30-12.35 SESSION VII: CYTOTOXIC CHEMOTHERAPY FOR ADVANCED DISEASE

Chairpersons:

Felipe Cardenal

ICO, Hospital Duran i Reynals, L'Hospitalet de Llobregat (Barcelona)

Sergio Vázquez

Hospital Univ. Lucas Augusti, Lugo

11.30-11.50 Role of chemotherapy in advanced disease: have we reached the bounds?

Antonio Araújo

Centro Hospitalar do Porto, Portugal

11.50-12.05 Molecular biology in advanced disease: beyond the targets

Fernando López-Ríos

CIOCC, Centro Integral Oncológico Clara Campal, Madrid

12.05-12.25 Making decisions in specific subpopulations: elderly and frail patients

Alain Vergenègre

Cluzeau University Hospital, Limoges (France)

12.25-12.40 Discussion

12.40-13.55 SESSION VIII: LUNG CANCER ONCOGENIC DRIVERS

Chairpersons:

Carlos Camps

Hospital General Universitario, Valencia

Nieves Galán

Hospital Clínico Univ. Lozano Blesa, Zaragoza

12.40-12.55 EGFR mutations beyond the first line therapy setting

Teresa Morán

ICO, Hospital Univ. Germans Trias i Pujol, Badalona (Barcelona)

12.55-13.15 ALK translocations: can we establish a sequence of drugs?

Ignacio Gil Bazo

Clínica Universitaria de Navarra, Pamplona (Navarra)

13.15-13.40 Resistance mechanisms: what is already known and what is still to know?

David Vicente

Hospital Univ. Virgen Macarena, Sevilla

13.40-13.55 Discussion

13.55-14.15 CLOSING

Organizing and Scientific Committee

Carlos Camps, *Hospital General Universitario, Valencia*
Enric Carcereny, *ICO, Hospital Germans Trias i Pujol, Badalona (Barcelona)*
Felipe Cardenal, *ICO, Hospital Duran i Reynals, L'Hospitalet de Llobregat (Barcelona)*
Manuel Cobo, *Hospital General Universitario Carlos Haya, Málaga*
Ramón de las Peñas, *Consortio Hospital Provincial, Castellón*
Manuel Dómine, *Fundación Jiménez Díaz, Madrid*
Nieves Galán, *Hospital Clínico Universitario Lozano Blesa, Zaragoza*
M^a Rosario García Campelo, *Complejo Hospitalario Universitario, A Coruña*
José Luis González Larriba, *Hospital Clínico San Carlos, Madrid*
Bartomeu Massutí, *Hospital General Universitario, Alicante*
Mariano Provencio, *Hospital Universitario Puerta de Hierro, Majadahonda (Madrid)*
Noemí Reguart, *Hospital Clínic, Barcelona*
Delvys Rodríguez, *Hospital Univ. Insular de Gran Canaria, Las Palmas de Gran Canaria*
Ivana G. Sullivan, *Hospital de la Santa Creu i Sant Pau, Barcelona*

Supporting Companies

Major sponsors:



Other sponsors:



Credits

Activitat acreditada pel Consell Català de la Formació Continuada de les Professions Sanitàries (CCFCPS) – Comisión de Formación Continuada del Sistema Nacional de Salud con **1,8 CRÉDITOS**, expedient núm.: 09/017262-MD.



Under the auspices of



Language

Lectures will be delivered in English or in Spanish.

Venue

Auditorio de la Mutua Madrileña
Pº de la Castellana, 33
28046 Madrid

Holding a badge will be required to access the meeting room.

Symposium Secretariat



www.doctaforum.com/gecp